Preimplantation Genetic Testing for Aneuploidy: Current Perspectives

L’Heveder, Ariadne; Jones, Benjamin P; Naja, Roy; Serhal, Paul; Nagi, Jara Ben

doi:10.1055/s-0041-1731828

Cited by 8 publications

(5 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1, and were excluded from the study. The most common reasons for exclusion were that the article concerned a conference abstract [13][14][15][16][17][18][19], absence of relevant inclusion criteria , absence of published study results [50,51], absence of a control group [52][53][54][55][56][57][58][59][60][61][62][63], and some studies [64][65][66][67][68] were review articles.…”

Section: Resultsmentioning

confidence: 99%

Preimplantation genetic testing for aneuploidy in patients of different age: a systematic review and meta-analysis

Adamyan,

Pivazyan,

Obosyan

et al. 2024

Obstet Gynecol Sci

View full text Add to dashboard Cite

This study aimed to summarize the current knowledge on the benefits of in vitro fertilization/intracytoplasmic sperm injection with preimplantation genetic testing for aneuploidy (PGT-A) and to discuss the role of PGT-A in patients of different ages undergoing assisted reproduction. A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 checklist.Registration number: CRD42022354697. Studies were identified by searching the PubMed, Cochrane Library, Google Scholar, Scopus, Embase, and ClinicalTrials databases. Seven meta-analyses were performed with additional stratification of age and prognosis of the women studied. Clinical pregnancy rate per embryo transfer in patients aged >35 years was higher in the PGT-A group (P=0.0002) than in controls. Live birth rate (LBR) per embryo transfer in women 35 years old or younger (P=0.002) was higher in the PGT-A group. The LBR per patient in women aged >35 years was higher in the PGT-A group (P=0.004). The effects of PGT-A on LBR in patients with poor prognosis showed a statistically significant increase (P=0.003). There was no significant difference in the rate between the two groups.PGT-A is effective and can be recommended for patients aged >35 years undergoing assisted reproduction to improve their reproductive outcomes. Moreover, our study showed the possible benefits of PGT-A in patients with a poor prognosis. Overall, our findings suggest that PGT-A is a valuable tool for improving the reproductive outcomes of assisted reproductive procedures in older women and those with a history of pregnancy complications.

show abstract

Section: Resultsmentioning

confidence: 99%

Preimplantation genetic testing for aneuploidy in patients of different age: a systematic review and meta-analysis

Adamyan,

Pivazyan,

Obosyan

et al. 2024

Obstet Gynecol Sci

View full text Add to dashboard Cite

show abstract

“…The main reason for poor reproductive outcomes in patients with advanced maternal age, recurrent abortion and repetitive implantation failure is believed to be the high incidence of embryo aneuploidy [22] . One study showed that a PGT-A diagnosis of uniform aneuploidy provides a 98% predictive value for early lethality and a 86.3% miscarriage rate [23] .…”

Section: Discussionmentioning

confidence: 99%

The comparision among euploidy of preimplantation blastocysts in different controlled ovary stimulation (COH) protocols

Wang,

Xu,

Yin

et al. 2024

Arch Gynecol Obstet

View full text Add to dashboard Cite

To compare differences in euploidy rates for blastocysts in preimplantation genetic testing for aneuploidy (PGT-A) cycles after gonadotropin-releasing hormone agonist (GnRH-a) long and short protocols, GnRH-antagonist (GnRH-ant) protocol, progestin-primed ovarian stimulation and mild stimulation protocols, and other ovary stimulation protocols. MethodsThis was a retrospective cohort study from the Assisted Reproductive Medicine Department of Shanghai First Maternity and Infant Hospital. A total of 1657 PGT-A cycles with intracytoplasmic sperm injection after different controlled ovary hyperstimulation protocols were analyzed, and a total of 3154 embryos were biopsied. Differences in euploidy rate per embryo biopsied, embryo euploidy rate per oocyte retrieved and cycle cancellation rate were compared. ResultsFor the PGT-A cycles, the euploidy rate per embryo biopsied was lower in the GnRH-ant protocol than in the GnRH-a long protocol (53.26% vs. 58.68%, respectively). Multiple linear regression showed that the GnRH-ant protocol was associated with a lower euploidy rate per embryo biopsied (β = −0.079, P = 0.011). The euploidy rate per embryo biopsied was not affected by total gonadotropin dosage, duration of stimulation and number of oocytes retrieved. The embryo euploidy rate per oocyte retrieved was similar in all protocols, and was negatively correlated with the total number of oocytes retrieved (β = −0.003, P = 0.003). ConclusionCompared with the GnRH-a long protocol, the GnRH-ant protocol was associated with a lower euploidy rate per embryo biopsied. The total gonadotropin dosage, duration of stimulation and number of oocytes retrieved did not appear to signi cantly in uence euploidy rates.What does this study adds to the clinical work I. Of guiding signi cance selecting clinical ovarian stimulation protocols and obtaining higher quality embryos.II. provides direction and reference for future research into the safety and application of GnRH antagonists.

show abstract

“…This technique is particularly important as a screening test for preimplanted embryo investigation, as it is a noninvasive tool for embryo assessment, avoiding the harmful consequences that may be derived from the invasive manipulations of embryos and could disturb normal development. 24…”

Section: ■ Experimental Sectionmentioning

confidence: 99%

Noninvasive Pregestational Genetic Testing of Embryos Using Smart Sensors Array

et al. 2022

View full text Add to dashboard Cite

Pregestational genetic testing of embryos is the conventional tool in detecting genetic disorders (fetal aneuploidy and monogenic disorders) for in vitro fertilization (IVF) procedures. The accepted clinical practice for genetic testing still depends on biopsy, which has the potential to harm the embryo. Noninvasive genetic prenatal testing has not yet been achieved. In this study, embryos with common genetic disorders created through IVF were tested with an artificially intelligent nanosensor array. Volatile organic compounds emitted by the culture fluid of embryos were analyzed with chemical gas sensors. The obtained results showed significant discrimination between the embryos with different genetic diseases and their wild-types. Embryos were obtained from the same clinical center for avoiding differences based on clinical and demographical characteristics. The achieved discrimination accuracy was 81% for PKD disease, 90% for FRAX disease, 85% for HOCM disease, 90% for BRCA disease, and 100% for HSCR disease. These proof-of-concept findings might launch the development of a noninvasive approach for early assessment of embryos by examining the culture fluid of the embryos, potentially enabling noninvasive diagnosis and screening of genetic diseases for IVF.

show abstract

Preimplantation Genetic Testing for Aneuploidy: Current Perspectives

Cited by 8 publications

References 59 publications

Preimplantation genetic testing for aneuploidy in patients of different age: a systematic review and meta-analysis

Preimplantation genetic testing for aneuploidy in patients of different age: a systematic review and meta-analysis

The comparision among euploidy of preimplantation blastocysts in different controlled ovary stimulation (COH) protocols

Noninvasive Pregestational Genetic Testing of Embryos Using Smart Sensors Array

Contact Info

Product

Resources

About